Overview
- President Claudia Sheinbaum announced a memorandum between the Health Ministry, Birmex, Liomont and Moderna to produce mRNA vaccines in Mexico, beginning with Moderna’s COVID-19 shot.
- The plan phases in local production from fill-and-finish to full drug‑substance manufacturing, including mRNA and lipid nanoparticles, and contemplates installing a domestic mRNA vaccine plant.
- Liomont will serve as licensee, sanitary‑registration holder and local supplier of Moderna’s mRNA vaccines, while state‑owned Birmex will participate in commercialization.
- The government outlined procurement of 10 million mRNA doses per year from 2025 to 2030—60 million total—stating these purchases were already in its annual planning.
- Officials have not released firm timelines or investment figures; a Moderna Latin America executive projected a 4–5 year implementation and flagged COFEPRIS timing as critical, as the announcement comes during a national measles outbreak driving expanded vaccination efforts.